Evidence map›Paper›PMID 28225992›Full record

ArticleArchives of endocrinology and metabolism

Serum Fluorescent Advanced Glycation End (F-AGE) products in gestational diabetes patients.

João Paulo Lobo, Catiane Pompilio Brescansin, Izabella C R Santos-Weiss, Marciane Welter, Emanuel Maltempi de Souza, Fabiane Gomes de Moraes Rego, Geraldo Picheth, Dayane Alberton

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Comparison of glucose degradation product and receptor levels in diabetic and normal pregnancyJournal of the Turkish German Gynecological Association · 2021
    Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

João Paulo LoboPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Catiane Pompilio BrescansinPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Izabella C R Santos-WeissPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Marciane WelterPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Emanuel Maltempi de SouzaDepartamento de Bioquímica e Biologia Molecular, UFPR, Curitiba, PR, Brasil.
Fabiane Gomes de Moraes RegoPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Geraldo PichethPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.
Dayane AlbertonPós-Graduação em Ciências Farmacêuticas, Departamento de Análise Clínica, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAdvanced glycation end products (AGEs) are involved in the pathogenesis and complications of diabetes mellitus (DM). Gestational DM (GDM) is characterized by increased glycemia and oxidative stress, which are factors associated with high serum AGE concentrations. The aim of this study was to evaluate the utility of a serum fluorescence AGE (F-AGE) method as a screening tool for gestational diabetes. SUBJECTS AND

methodsSerum samples from 225 GDM patients and 217 healthy pregnant women (healthy controls) were diluted 50-fold in phosphate-buffered saline, and the AGEs were estimated by fluorometric analysis (λEx 350 nm/ λEm 440 nm).

resultsNo significant (P > 0.05) differences in AGE concentrations, expressed in Arbitrary Units (UA/mL × 104), were observed in the women with GDM or in the healthy controls. Furthermore, F-AGE concentrations did not change significantly during the pregnancy (12-32 weeks of gestation). Only the GDM group had a positive correlation (r = 0.421; P < 0.001) between F-AGEs and serum creatinine concentrations.

conclusionIt was not possible to distinguish women with gestational diabetes from the healthy controls on the basis of serum F-AGE concentrations.

Indexed as

AdultAnalysis of VarianceAnthropometryBlood GlucoseCase-Control StudiesCreatinineDiabetes, GestationalFemaleFluorometryGestational AgeGlycation End Products, AdvancedHumansMass ScreeningPregnancyReference ValuesReproducibility of ResultsBlood GlucoseCreatinineGlycation End Products, Advanced

Identifiers

PMID28225992
PMCPMC10118810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.